Vector VestAdvertisement SPDR Advertisement
Home > Boards > US Listed > Biotechs >

Cel-Sci (CVM)

CVM RSS Feed
Add CVM Price Alert      Hide Sticky   Hide Intro
Moderator: No Moderator Foxwoods Man, drkazmd65
Search This Board:
Last Post: 1/26/2015 8:07:35 PM - Followers: 163 - Board type: Free - Posts Today: 0

 Cel-Sci Corporation (CVM)

http://www.cel-sci.com/



Products In Development

Multikine® (Leukocyte Interleukin, Injection) is the full name of this investigational therapy, which, for simplicity, is referred to in the remainder of this page as Multikine*.

CANCER - MULTIKINE

Multikine, CEL-SCI's lead investigational immunotherapy, is an immunotherapeutic agent that is being developed as a potential first-line treatment for advanced primary head and neck cancer. If it were to be approved for use following completion of CEL-SCI's clinical development program, Multikine would be a different kind of therapy in the fight against cancer; one that appears to have the potential to work with the body's natural immune system in the fight against tumors.

Multikine may also have the potential to be a first in a new class of cancer immunotherapy drugs. It is the first investigational combination immunotherapy thought to have both passive and active immune properties.  More...

INFECTIOUS DISEASES - L.E.A.P.S.(TM)**

L.E.A.P.S is a patented, T-cell modulation, peptide epitope delivery technology that enables CEL-SCI to design and synthesize proprietary peptide immunogens. L.E.A.P.S. compounds consist of a small T-cell binding peptide ligand linked with a disease-associated peptide antigen.

This new technology has been shown the potential in several animal models to preferentially direct immune response to a cellular (e.g., T-cell), humoral (antibody) or mixed pathway. Diseases for which antigenic epitope sequences have been identified, such as some infectious diseases, cancer, autoimmune diseases, allergic asthma and allergy, and select CNS diseases (e.g., Alzheimer's) may be potential candidates for development using this technology platform.  More...

 

* Multikine is the trademark that CEL-SCI has registered for this investigational therapy, and this proprietary name is subject to FDA review in connection with our future anticipated regulatory submission for approval. Multikine has not been licensed or approved for sale, barter or exchange by the FDA or by any other regulatory agency. Similarly, its safety of efficacy has not been established for any use. Moreover, no definitive conclusions can be drawn from the early-phase, clinical-trials data summarized on this page or elsewhere on this website involving the investigational therapy Multikine (Leukocyte Interleukin, Injection). Further research is required, and early-phase clinical trial results must be confirmed in the well-controlled, Phase III clinical trial of this investigational therapy that is currently in progress.

** L.E.A.P.S. is the trademark of CEL-SCI for this investigational platform technology, and this proprietary name is subject to FDA review. No L.E.A.P.S. product has been approved for sale, barter or exchange by the FDA or any other regulatory agency for any use to treat disease in animals or humans. The safety or efficacy of these products has not been established for any use. Lastly, no definitive conclusions can be drawn from these early-phase, preclinical-trials data involving these investigational products

Partnering Philosophy & Corporate Partners

CEL-SCI's partnering philosophy is guided by the belief that any partnership entered into should serve the best interests of: 

  1. The patients who are/will be treated,
  2. The scientific, clinical, and commercial development of the medicine and
  3. CEL-SCI's shareholders.

CEL-SCI is open to any reasonable partnership proposals that will accelerate its being able to bring its medicines to market.

Multikine® (Leukocyte Interleukin, Injection):

Multikine (Leukocyte Interleukin, Injection) is the full name of this investigational therapy, which, for simplicity, is referred to in the remainder of this page as Multikine*.

CEL-SCI has a unique expertise in the development and manufacture of complex biologics. CEL-SCI is not a company that markets and sells drug products at the current time. Regardless, CEL-SCI believes it will be capable of marketing and selling Multikine on its own for head and neck cancer in both the United States and Europe if and once it is approved by the FDA (or EU regulators). Since its primary target is head & neck cancer surgeons, a rather small audience, CEL-SCI does not believe that a large sales force will be needed to commercialize Multikine, if and once it is approved by the FDA (or EU regulators) following the review of the total Multikine Biologics License Application.

Current Corporate Partners:

  1. Byron Biopharma
      a. Agreement Signed March 2009  
      b. Territory - Republic of South Africa  
      c. Revenue Share  
  2. Teva Pharmaceuticals Industries Ltd.
      a. Agreement Signed August 2008  
      b. Territory - Israel, Turkey, expanded to also cover Serbia and Croatia in August 2011.  
      c. Revenue Share  
      d. Website - http://www.tevapharm.com/  
  3.  
  4. Orient Europharma Co. Ltd.
      a. Agreement Signed November 2000  
      b. Territory - Taiwan, Singapore, Hong Kong, Malaysia, expanded to also cover South Korea, the Philippines, Australia and New Zealand in the Fall of 2008.  
      c. Revenue Share  
      d. Website - http://www.oep.com.tw/  
  5.  
  6. IDC-GP Pharm LLC 
      a. Agreement signed August 2011  
      b. Territory - Argentina and Venezuela  
      c. Revenue Share  
      d. Website - http://www.gp-pharm.com/  
  7.  

Other Partnering Possibilities:

Based on the Company's L.E.A.P.S.TM** technology, as long as a disease epitope is available, CEL-SCI may be able to develop an effective treatment/vaccine using the L.E.A.P.S. technology.  The two leading candidates derived from this technology are the H1N1 treatment being developed as a possible treatment option for hospitalized patients and the Rheumatoid Arthritis treatment vaccine currently being tested in animal models of the disease.

 

* Multikine is the trademark that CEL-SCI has registered for this investigational therapy, and this proprietary name is subject to FDA review in connection with our future anticipated regulatory submission for approval. Multikine has not been licensed or approved for sale, barter or exchange by the FDA or any other regulatory agency. Similarly, its safety or efficacy has not been established for any use. Moreover, no definitive conclusions can be drawn from the early-phase, clinical-trials data summarized on this page or elsewhere on this website involving the investigational therapy Multikine (Leukocyte Interleukin, Injection). Further research is required, and early-phase clinical trial results must be confirmed in the well-controlled, Phase III clinical trial of this investigational therapy that is currently in progress.

** L.E.A.P.S. is the trademark of CEL-SCI for this investigational platform technology, and this proprietary name is subject to FDA review. No L.E.A.P.S. product has been approved for sale, barter or exchange by the FDA or any other regulatory agency for any use to treat disease in animals or humans. The safety or efficacy of these products has not been established for any use. Lastly, no definitive conclusions can be drawn from these early-phase, preclinical-trials data involving these investigational products.




http://stockcharts.com/freecharts/gallery.html?CVM

http://finance.yahoo.com/q?s=cvm&ql=1

http://stockcharts.com/h-sc/ui?s=CVM&p=D&yr=3&mn=0&dy=0&id=p60195179833

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
CVM
Current Price
Volume:
Bid Ask Day's Range
Wiki
CVM News: CEL-SCI Receives Regulatory Clearance to Expand Its Phase III Head and Neck Cancer Trial into Romania 01/26/2015 09:00:00 AM
CVM News: Statement of Changes in Beneficial Ownership (4) 01/09/2015 10:34:25 AM
CVM News: Statement of Changes in Beneficial Ownership (4) 01/09/2015 10:28:21 AM
CVM News: Statement of Changes in Beneficial Ownership (4) 01/09/2015 10:21:25 AM
CVM News: Statement of Changes in Beneficial Ownership (4) 01/09/2015 10:17:55 AM
News News Alert: CEL-SCI Receives Regulatory Clearance to Expand Its Phase III Head and Neck Cancer Trial into Romania 01/26/2015 09:00:00 AM
PostSubject
#6215  Sticky Note http://www.marketwatch.com/story/small-companies-lead-the-i-o-class-of-cancer-th majatamata 08/08/14 11:00:50 AM
#5747  Sticky Note They keep coming!! Foxwoods Man 04/02/14 08:51:19 AM
#6590   I saw that as well...2 trades half hour maverick1856 01/26/15 08:07:35 PM
#6589   Showing .84 after hours high. Very unusual. Could peterose 01/26/15 06:35:19 PM
#6588   And now we can add another country to drkazmd65 01/26/15 10:03:01 AM
#6587   It's a real shame cvm stock is a peterose 01/17/15 08:45:25 PM
#6586   I really hope we do not have another peterose 01/17/15 08:40:19 PM
#6585   I hope it does not stay level at maverick1856 01/17/15 12:39:18 PM
#6584   While the arbitration ruling may be immediate and Paleman 01/17/15 09:27:05 AM
#6583   The arbitration award if won is immediafe funds peterose 01/15/15 02:01:39 PM
#6582   Re the arbitration hearing (trial), while we all Paleman 01/15/15 08:52:34 AM
#6581   A higher pps somehow someway asap is imperative peterose 01/14/15 05:44:13 PM
#6580   Highrt enrollment numbers mean new investors. Right now peterose 01/14/15 05:38:30 PM
#6579   Hmmm..I would think the major cash outlay is Foxwoods Man 01/14/15 04:00:39 PM
#6578   Disagree, they need to enroll around 20 patients...keep maverick1856 01/14/15 01:20:19 PM
#6577   CVM must enroll at least 40-50 patients this peterose 01/14/15 12:21:36 PM
#6576   I am in St. Maarten where the weather Foxwoods Man 01/13/15 08:37:55 PM
#6575   Don't think their buys. Incentive based. when they peterose 01/13/15 06:20:12 PM
#6574   Are those insider acquisitions filed on 1/9/2015 open maverick1856 01/13/15 07:14:03 AM
#6573   He didn't present until 2:30 eastern. Stock was peterose 01/12/15 07:38:46 PM
#6572   Record is intact...every time he speaks the stock Foxwoods Man 01/12/15 06:37:07 PM
#6571   I thought Kersten did a good job with peterose 01/12/15 05:31:39 PM
#6570   The person who wrote the analyst coverage is peterose 01/12/15 05:27:24 PM
#6569   Live broadcast interesting. Mostly a rehash of know Turney 01/12/15 03:09:13 PM
#6568   Only 3 companies where they initiated coverage on jap1511 01/12/15 02:52:46 PM
#6567   Thanks for the report. It helped us ducruacuteo11 01/12/15 10:52:57 AM
#6566   Cel Sci - Updated analysis and Price target maverick1856 01/12/15 08:16:11 AM
#6565   I won't worry UNTIL they have trouble sellin' Turney 01/10/15 08:13:27 PM
#6564   Maybe....but more exposure (press) brings more investors and Foxwoods Man 01/10/15 10:57:07 AM
#6563   I've been investing in CVM since 1998 so Turney 01/10/15 10:45:58 AM
#6562   My Prediction.. Dilution coming within next 60 days.. Thinking-Longterm 01/09/15 10:12:11 PM
#6561   There is a live audio webcast through the peterose 01/09/15 10:38:38 AM
#6560   Date : 01/09/2015 @ 8:30AM Foxwoods Man 01/09/15 08:59:20 AM
#6559   Correct...but "positive preliminary findings" can be reported ahead Foxwoods Man 01/09/15 08:19:29 AM
#6558   Or for that matter am not aware of kurious 01/08/15 06:14:49 PM
#6557   I stand corrected then,... hadn't seen any stock drkazmd65 01/08/15 04:16:25 PM
#6556   I beg to differ with you on one peterose 01/08/15 04:12:29 PM
#6555   Thanks, drkazmd65! I stumbled across this board ducruacuteo11 01/08/15 04:03:09 PM
#6554   Greetings ducruacuteo11 - welcome to the board. drkazmd65 01/08/15 02:48:12 PM
#6553   New to the board. I have been ducruacuteo11 01/08/15 11:35:18 AM
#6552   Yes, that's the conventional wisdom. But Big Pharma Turney 01/08/15 07:54:09 AM
#6551   I would rather cvm partner up with big peterose 01/07/15 07:58:27 PM
#6550   It's the nature of the beast....unless they get Foxwoods Man 01/07/15 05:44:26 PM
#6549   As the pps moves higher; the realization of peterose 01/07/15 05:22:19 PM
#6548   Yep,... a nice trend to see. drkazmd65 01/07/15 04:39:40 PM
#6547   Also noted: CVM hasn't closed above .70 since Foxwoods Man 01/07/15 04:24:31 PM
#6546   As I hoped the article that brought up Foxwoods Man 01/07/15 03:33:04 PM
#6545   You have two kinds of Arbitration; BINDING with Turney 01/07/15 03:06:57 PM
#6544   If we're looking at May for trial, look peterose 01/06/15 11:36:06 AM
#6543   Agreed on both points - unless they 'know' drkazmd65 01/06/15 11:17:15 AM
#6542   Exactly. I thought an arbitrator hears both sides peterose 01/06/15 09:45:05 AM
#6541   It could be semantics and they could be Foxwoods Man 01/06/15 09:42:52 AM
PostSubject